{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:37:55Z","timestamp":1773747475066,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40272-022-00491-5","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T01:02:16Z","timestamp":1643245336000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety of Ferric Carboxymaltose in Children: Report of a Case Series from Greece and Review of the Literature"],"prefix":"10.1007","volume":"24","author":[{"given":"Paraskevi","family":"Panagopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Alexiadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ntoumpara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Makis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Fotoulaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7837-9733","authenticated-orcid":false,"given":"Elpis","family":"Mantadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"4","key":"491_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.hoc.2014.04.007","volume":"28","author":"JM Powers","year":"2014","unstructured":"Powers JM, Buchanan GR. Diagnosis and management of iron deficiency anemia. Hematol Oncol Clin N Am. 2014;28(4):729\u201345.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"11","key":"491_CR2","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/archpedi.159.11.1038","volume":"159","author":"JM Brotanek","year":"2005","unstructured":"Brotanek JM, Halterman JS, Auinger P, Flores G, Weitzman M. Iron deficiency, prolonged bottle-feeding, and racial\/ethnic disparities in young children. Arch Pediatr Adolesc Med. 2005;159(11):1038.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"40","key":"491_CR3","first-page":"897","volume":"51","author":"Centers for Disease Control and Prevention (CDC)","year":"2002","unstructured":"Centers for Disease Control and Prevention (CDC). Iron deficiency\u2013United States, 1999\u20132000. MMWR Morb Mortal Wkly Rep. 2002;51(40):897\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"491_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/j.ackd.2005.07.008","volume":"12","author":"LA Greenbaum","year":"2005","unstructured":"Greenbaum LA. Anemia in children with chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(4):385\u201396.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"491_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1177\/1060028017699429","volume":"51","author":"N Hassan","year":"2017","unstructured":"Hassan N, Boville B, Reischmann D, Ndika A, Sterken D, Kovey K. Intravenous ferumoxytol in pediatric patients with iron deficiency anemia. Ann Pharmacother. 2017;51(7):548\u201354.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"491_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","volume":"9","author":"AU Dignass","year":"2015","unstructured":"Dignass AU, Gasche C, Bettenworth D, Birgeg\u00e5rd G, Danese S, Gisbert JP, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211\u201322.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"491_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.crohns.2011.12.001","volume":"6","author":"AE Wiskin","year":"2012","unstructured":"Wiskin AE, Fleming BJ, Wootton SA, Beattie RM. Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis. 2012;6(6):687\u201391.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"491_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/01.MIB.0000442728.74340.fd","volume":"20","author":"N Filmann","year":"2014","unstructured":"Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20(5):936\u201345.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"491_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ibd.21740","volume":"18","author":"JR Goodhand","year":"2012","unstructured":"Goodhand JR, Kamperidis N, Rao A, Laskaratos F, Mcermott A, Wahed M, et al. Prevalence and management of anemia in children, adolescents and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):513\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"491_CR10","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1097\/MIB.0b013e31829ed855","volume":"19","author":"K Gerasimidis","year":"2013","unstructured":"Gerasimidis K, Barclay A, Papangelou A, Missiou D, Buchanan E, Tracey C, et al. The epidemiology of anemia in pediatric inflammatory bowel disease: prevalence and associated factors at diagnosis and follow-up and the impact of exclusive enteral nutrition. Inflamm Bowel Dis. 2013;19(11):2411\u201322.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"491_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12098-012-0906-6","volume":"80","author":"VN Yewale","year":"2013","unstructured":"Yewale VN, Dewan B. Treatment of iron deficiency anemia in children: a comparative study of ferrous ascorbate and colloidal iron. Indian J Pediatr. 2013;80(5):385\u201390.","journal-title":"Indian J Pediatr"},{"issue":"1","key":"491_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/pbc.25752","volume":"63","author":"E Mantadakis","year":"2016","unstructured":"Mantadakis E. Advances in pediatric intravenous iron therapy: intravenous iron therapy in children. Pediatr Blood Cancer. 2016;63(1):11\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"491_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jpeds.2016.09.053","volume":"180","author":"JM Powers","year":"2017","unstructured":"Powers JM, Shamoun M, McCavit TL, Adix L, Buchanan GR. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. J Pediatr. 2017;180:212\u20136.","journal-title":"J Pediatr"},{"issue":"3","key":"491_CR14","first-page":"296","volume":"12","author":"M Auerbach","year":"2014","unstructured":"Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 2014;12(3):296\u2013300.","journal-title":"Blood Transfus"},{"issue":"3","key":"491_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.iac.2014.04.013","volume":"34","author":"AJ Bircher","year":"2014","unstructured":"Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin N Am. 2014;34(3):707\u201323.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"1","key":"491_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","volume":"90","author":"T Avni","year":"2015","unstructured":"Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12\u201323.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"491_CR17","doi-asserted-by":"publisher","first-page":"e27016","DOI":"10.1002\/pbc.27016","volume":"65","author":"E Mantadakis","year":"2018","unstructured":"Mantadakis E. Intravenous iron: Safe and underutilized in children. Pediatr Blood Cancer. 2018;65(6):e27016.","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"491_CR18","first-page":"691","volume":"100","author":"AM Ganzoni","year":"1970","unstructured":"Ganzoni AM. New aspects of iron deficiency. Schweiz Med Wochenschr. 1970;100(16):691\u20137.","journal-title":"Schweiz Med Wochenschr"},{"key":"491_CR19","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (Version 5.0). US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. November 2017."},{"issue":"5","key":"491_CR20","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/bcp.13189","volume":"83","author":"P Bager","year":"2017","unstructured":"Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017;83(5):1118\u201325.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"491_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","volume":"26","author":"H Zoller","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266\u201375.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9","key":"491_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/jpc.15662","volume":"57","author":"KH McGrath","year":"2021","unstructured":"McGrath KH, Khoo PWR. Hypophosphataemia following ferric carboxymaltose infusion. J Paediatr Child Health. 2021;57(9):1546.","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"491_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/flgastro-2019-101242","volume":"11","author":"RE Harris","year":"2019","unstructured":"Harris RE, Armstrong L, Curtis L, Garrick V, Gervais L, Tayler R, et al. Severe hypophosphataemia following ferric carboxymaltose infusion in paediatric patients with inflammatory bowel disease. Frontline Gastroenterol. 2019;11(4):324\u20136.","journal-title":"Frontline Gastroenterol."},{"issue":"4","key":"491_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/archdischild-2018-316405","volume":"105","author":"RE Harris","year":"2020","unstructured":"Harris RE, Garrick V, Curtis L, Russell RK. Skin staining due to intravenous iron extravasation in a teenager with Crohn\u2019s disease. Arch Dis Child. 2020;105(4):362.","journal-title":"Arch Dis Child"},{"key":"491_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1471-230X-14-184","volume":"14","author":"MW Laass","year":"2014","unstructured":"Laass MW, Straub S, Chainey S, Virgin G, Cushway T. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. BMC Gastroenterol. 2014;14:184.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"491_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00431-017-2995-8","volume":"176","author":"MLN Tan","year":"2017","unstructured":"Tan MLN, Windscheif P-M, Thornton G, Gaynor E, Rodrigues A, Howarth L. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. Eur J Pediatr. 2017;176(10):1419\u201323.","journal-title":"Eur J Pediatr"},{"key":"491_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jpeds.2017.01.041","volume":"184","author":"E Mantadakis","year":"2017","unstructured":"Mantadakis E, Roganovic J. Safety and efficacy of ferric carboxymaltose in children and adolescents with iron deficiency anemia. J Pediatr. 2017;184:241.","journal-title":"J Pediatr"},{"issue":"1","key":"491_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/00365521.2016.1224381","volume":"52","author":"S Val\u00e9rio de Azevedo","year":"2017","unstructured":"Val\u00e9rio de Azevedo S, Maltez C, Lopes AI. Pediatric Crohn\u2019s disease, iron deficiency anemia and intravenous iron treatment: a follow-up study. Scand J Gastroenterol. 2017;52(1):29\u201333.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"491_CR29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bcp.13493","volume":"84","author":"M Papadopoulos","year":"2018","unstructured":"Papadopoulos M, Patel D, Korologou-Linden R, Goto E, Soondrum K, Fell JME, et al. Safety and efficacy of parenteral iron in children with inflammatory bowel disease: safety and efficacy of parenteral iron in children with IBD. Br J Clin Pharmacol. 2018;84(4):694\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"491_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.dld.2021.02.017","volume":"53","author":"L Cococcioni","year":"2021","unstructured":"Cococcioni L, Pensabene L, El-Khouly S, Chadokufa S, McCartney S, Saliakellis E, et al. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia. Dig Liver Dis. 2021;53(7):830\u20134.","journal-title":"Dig Liver Dis."},{"issue":"1","key":"491_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21037\/tp.2019.01.01","volume":"8","author":"N Carman","year":"2019","unstructured":"Carman N, Muir R, Lewindon P. Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease. Transl Pediatr. 2019;8(1):28\u201334.","journal-title":"Transl Pediatr."},{"issue":"12","key":"491_CR32","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/jpc.14686","volume":"55","author":"MH Hong","year":"2019","unstructured":"Hong MH, Singh H, Hinds R. Ferric carboxymaltose infusions are well tolerated in children under 14 years old, a single-centre experience. J Paediatr Child Health. 2019;55(12):1515\u20136.","journal-title":"J Paediatr Child Health"},{"issue":"10","key":"491_CR33","doi-asserted-by":"publisher","first-page":"e28614","DOI":"10.1002\/pbc.28614","volume":"67","author":"H Ozsahin","year":"2020","unstructured":"Ozsahin H, Schaeppi M, Bernimoulin M, Allard M, Guidard C, van den Ouweland F. Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents. Pediatr Blood Cancer. 2020;67(10):e28614.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"491_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/MPG.0000000000003003","volume":"72","author":"N Sasankan","year":"2021","unstructured":"Sasankan N, Duncan H, Curtis L, McGuckin C, Shannon C, Barclay A, et al. Ferric carboxymaltose across all ages in paediatric gastroenterology shows efficacy without increased safety concerns. J Pediatr Gastroenterol Nutr. 2021;72(4):506\u201310.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"491_CR35","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/apa.15178","volume":"109","author":"A Posod","year":"2020","unstructured":"Posod A, Schaefer B, Mueller T, Zoller H, Kiechl-Kohlendorfer U. Hypophosphatemia in children treated with ferric carboxymaltose. Acta Paediatr. 2020;109(7):1491\u20132.","journal-title":"Acta Paediatr"},{"issue":"6","key":"491_CR36","doi-asserted-by":"publisher","first-page":"E215","DOI":"10.1002\/ajh.26165","volume":"96","author":"SE Kirk","year":"2021","unstructured":"Kirk SE, Scheurer ME, Bernhardt MB, Mahoney DH, Powers JM. Phosphorus levels in children treated with intravenous ferric carboxymaltose. Am J Hematol. 2021;96(6):E215\u20138.","journal-title":"Am J Hematol"},{"issue":"23","key":"491_CR37","doi-asserted-by":"publisher","first-page":"e963","DOI":"10.1097\/MD.0000000000000963","volume":"94","author":"OH Nielsen","year":"2015","unstructured":"Nielsen OH, Ainsworth M, Coskun M, Weiss G. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine (Baltimore). 2015;94(23):e963.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"491_CR38","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1046\/j.1365-2036.2001.01113.x","volume":"15","author":"J Carrier","year":"2001","unstructured":"Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001;15(12):1989\u201399.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11\u201312","key":"491_CR39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1365-2036.2005.02700.x","volume":"22","author":"AD De Silva","year":"2005","unstructured":"De Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22(11\u201312):1097\u2013105.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"491_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gut.2010.216929","volume":"60","author":"T Werner","year":"2011","unstructured":"Werner T, Wagner SJ, Martinez I, Walter J, Chang JS, Clavel T, et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn\u2019s disease-like ileitis. Gut. 2011;60(3):325\u201333.","journal-title":"Gut"},{"issue":"5","key":"491_CR41","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/gutjnl-2014-307720","volume":"64","author":"T Jaeggi","year":"2015","unstructured":"Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64(5):731\u201342.","journal-title":"Gut"},{"issue":"10","key":"491_CR42","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/apt.14043","volume":"45","author":"A Aksan","year":"2017","unstructured":"Aksan A, I\u015f\u0131k H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1303\u201318.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"491_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/2040620714521127","volume":"5","author":"DB Bregman","year":"2014","unstructured":"Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5(2):48\u201360.","journal-title":"Ther Adv Hematol."},{"issue":"3","key":"491_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00005176-200203000-00011","volume":"34","author":"P Mamula","year":"2002","unstructured":"Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;34(3):286\u201390.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"491_CR45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/pbc.22930","volume":"56","author":"SE Crary","year":"2011","unstructured":"Crary SE, Hall K, Buchanan GR. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy: Iron Sucrose in Children. Pediatr Blood Cancer. 2011;56(4):615\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"491_CR46","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1097\/MPG.0000000000001383","volume":"63","author":"I Danko","year":"2016","unstructured":"Danko I, Weidkamp M. Correction of iron deficiency anemia with intravenous iron sucrose in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;63(5):e107\u201311.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"491_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12519-015-0010-x","volume":"12","author":"E Mantadakis","year":"2016","unstructured":"Mantadakis E, Tsouvala E, Xanthopoulou V, Chatzimichael A. Intravenous iron sucrose for children with iron deficiency anemia: a single institution study. World J Pediatr. 2016;12(1):109\u201313.","journal-title":"World J Pediatr."},{"issue":"5","key":"491_CR48","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1097\/MPH.0000000000000879","volume":"39","author":"K Kaneva","year":"2017","unstructured":"Kaneva K, Chow E, Rosenfield CG, Kell MJ. Intravenous iron sucrose for children with iron deficiency anemia. J Pediatr Hematol Oncol. 2017;39(5):e259\u201362.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"491_CR49","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/pbc.24676","volume":"60","author":"ES Plummer","year":"2013","unstructured":"Plummer ES, Crary SE, McCavit TL, Buchanan GR. Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. Pediatr Blood Cancer. 2013;60(11):1747\u201352.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"491_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/ph11030082","volume":"11","author":"S Bhandari","year":"2018","unstructured":"Bhandari S, Pereira D, Chappell H, Drakesmith H. Intravenous irons: from basic science to clinical practice. Pharmaceuticals. 2018;11(3):82.","journal-title":"Pharmaceuticals"},{"issue":"7","key":"491_CR51","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1007\/s12325-021-01770-2","volume":"38","author":"JA Glaspy","year":"2021","unstructured":"Glaspy JA, Wolf M, Strauss WE. Intravenous iron-induced hypophosphatemia: an emerging syndrome. Adv Ther. 2021;38(7):3531\u201349.","journal-title":"Adv Ther"},{"issue":"23","key":"491_CR52","doi-asserted-by":"publisher","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","volume":"3","author":"M Wolf","year":"2018","unstructured":"Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23):e124486.","journal-title":"JCI Insight."},{"issue":"5","key":"491_CR53","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432\u201343.","journal-title":"JAMA"},{"issue":"5","key":"491_CR54","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256\u201373.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"491_CR55","doi-asserted-by":"publisher","first-page":"e28726","DOI":"10.1002\/pbc.28726","volume":"68","author":"M Schmugge","year":"2021","unstructured":"Schmugge M, Mattiello V, Hengartner H, von der Weid N, Renella R, SPOG Pediatric Hematology Working Group. Comment on: Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: benefits and risks in a cohort of 144 children and adolescents. Pediatr Blood Cancer. 2021;68(3):e28726.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"491_CR56","doi-asserted-by":"publisher","first-page":"e26995","DOI":"10.1002\/pbc.26995","volume":"65","author":"AA Boucher","year":"2018","unstructured":"Boucher AA, Pfeiffer A, Bedel A, Young J, McGann PT. Utilization trends and safety of intravenous iron replacement in pediatric specialty care: a large retrospective cohort study. Pediatr Blood Cancer. 2018;65(6):e26995.","journal-title":"Pediatr Blood Cancer"},{"key":"491_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jpeds.2020.02.071","volume":"222","author":"AE Jacobson-Kelly","year":"2020","unstructured":"Jacobson-Kelly AE, Stanek JR, Powers JM, Dotson JL, O\u2019Brien SH. Trends in anemia, iron, therapy, and transfusion in hospitalized pediatric patients with inflammatory bowel disease. J Pediatr. 2020;222:141-5.e1.","journal-title":"J Pediatr"},{"key":"491_CR58","unstructured":"Clinical Trials. https:\/\/clinicaltrials.gov\/ct2\/results?cond=ferric+carboxymaltose&age_v=&age=0&gndr=&type=&rslt=&Search=Apply. Accessed 12 Jun 2021."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00491-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-022-00491-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-022-00491-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T09:28:14Z","timestamp":1666517294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-022-00491-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1007\/s40272-022-00491-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"5 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors Paraskevi Panagopoulou, Sonia Alexiadou, Maria Ntoumpara, Anna Papazoglou, Alexandros Makis, Athanasios Tragiannidis, and Maria Fotoulaki declare that they have no conflicts of interest relevant to the contents of this manuscript. Elpis Mantadakis has received support from Uni-pharma, maker of Hemafer-S<sup>\u00ae<\/sup>, a commercially available form of intravenous iron sucrose in Greece.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study was approved by the ethics committees of the participating hospitals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Applicable for the patients of the Greek cohort.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EM and PP conceived the article, performed the literature search, and wrote the manuscript. SA, MN, and AP helped with data collection and analysis. AM, AT, and MF contributed patients to the Greek cohort and helped with preparation, review, and editing of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}